Purdue Pharma | search
Click here to view Purdue Pharma news from 60+ newspapers.
Bookmark or Share- Bristol-Myers Squibb | Cafepharma Message Boards | Pharma Sales, Device ...Bristol-Myers Squibb | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales. Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page.
- Cafepharma | Pharmaceutical Sales, Medical Sales, Lab SalesFill in the blank. Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more.
- Boehringer Ingelheim | Cafepharma Message Boards | Pharma Sales, Device ...Boehringer Ingelheim | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales. Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page.
- Novartis | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab ...Pfizer Consumer Healthcare Pharmacyclics Phathom Pharmaceuticals Pinnacle Biologics Poly Pharmaceuticals Procter & Gamble Prometheus Labs Promius Pharma ProPharma Sales PruGen Puma Biotechnology Purdue Questcor Radius Health Ranbaxy Reckitt Benckiser Regeneron Relypsa Revance Biotech Rion Health Ritedose Roche Romark RVL Pharmaceuticals Sage ...
- Johnson & Johnson | Cafepharma Message Boards | Pharma Sales, Device ...Johnson & Johnson | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales. Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page.
More
